Key result
CRT fails to restore reduced regulatory T cell levels in chronic HF.
Why the study?
The impact of cardiac resynchronization therapy on the inflammatory immune response and T cells in chronic heart failure remains controversial.
Does cardiac resynchronization therapy improve T cell subpopulations and inflammatory response in patients with advanced heart failure?
Comparison
Pre-CRT (T0) vs 6 months post-CRT (T6) and healthy controls
Design
Observational and prospective study
Follow-up
6 months
Authors
Loading...
CRT may not fully reverse immune dysregulation in HF despite remodeling; leaves open whether adjunct immunomodulation is needed.
Observational (n=50)
No
Does cardiac resynchronization therapy improve T cell subpopulations and inflammatory response in patients with advanced heart failure?
Absolute Event Rate: 0.61% vs 1.08%
p-value: p=0.003
Cardiac resynchronization therapy does not restore the reduced levels of regulatory T cells in chronic heart failure patients, suggesting that the underlying inflammatory condition continues to evolve despite reverse remodeling.
Martins et al. (2023) conducted an observational in Chronic heart failure (n=50). Cardiac resynchronization therapy (CRT) vs. Healthy control group was evaluated on Frequency of regulatory T (Treg) cells (%) (p=0.003). Cardiac resynchronization therapy did not restore the significantly reduced levels of regulatory T cells in patients with chronic heart failure after 6 months of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: